A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models

Frequent infusions of intravenous factor VIII (FVIII) are required to prevent bleeding associated with hemophilia A. To reduce the treatment burden, recombinant FVIII with a longer half-life was developed without changing the protein structure. FVIII–polyethylene glycol (PEG) conjugates were prepare...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Stennicke, Henning R., Kjalke, Marianne, Karpf, Ditte M., Balling, Kristoffer W., Johansen, Peter B., Elm, Torben, Øvlisen, Kristine, Möller, Flemming, Holmberg, Heidi L., Gudme, Charlotte N., Persson, Egon, Hilden, Ida, Pelzer, Hermann, Rahbek-Nielsen, Henrik, Jespersgaard, Christina, Bogsnes, Are, Pedersen, Anette A., Kristensen, Anne K., Peschke, Bernd, Kappers, Wendy, Rode, Frederik, Thim, Lars, Tranholm, Mikael, Ezban, Mirella, Olsen, Eva H. N., Bjørn, Søren E.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2013
Materias:
Thrombosis and Hemostasis
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3596971/
https://ncbi.nlm.nih.gov/pubmed/23335368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-01-407494
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares